Molecular Profile Detail

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
HRAS Q61R	Advanced Solid Tumor	sensitive		Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).	26544513
HRAS Q61R	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Mektovi (binimetinib) in culture (PMID: 26544513).	26544513
HRAS Q61R	bladder urothelial carcinoma	predicted - sensitive		Tipifarnib	Case Reports/Case Series	Actionable	In a Phase II trial, Zarnestra (tipifarnib) demonstrated manageable toxicity profile, resulted in an objective response rate of 33.3% (5/15) in patients with transitional cell carcinoma harboring HRAS mutations, 2 patients with bladder urothelial carcinoma harbored HRAS Q61R achieved partial responses (PMID: 32636318; NCT02535650).	32636318

Profile Name	HRAS Q61R
Gene Variant Detail	HRAS Q61R (loss of function)
Relevant Treatment Approaches	MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor PI3K Inhibitor (Pan) PIK3CA inhibitor PIK3CB inhibitor PIK3CD inhibitor PIK3CG inhibitor RAS Inhibitor (Pan)